Byotrol Plc

-0.10 (-5.13%)
Share Name Share Symbol Market Type Share ISIN Share Description
Byotrol Plc LSE:BYOT London Ordinary Share GB00B0999995 ORDS 0.25P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.10 -5.13% 1.85 1,065,115 12:44:23
Bid Price Offer Price High Price Low Price Open Price
1.80 1.90 1.95 1.85 1.95
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Chemicals & Chem Preps, Nec 6.33 -1.35 -0.30 - 8.40
Last Trade Time Trade Type Trade Size Trade Price Currency
12:44:23 O 130,000 1.90 GBX

Byotrol (BYOT) Latest News

Byotrol (BYOT) Discussions and Chat

Byotrol Forums and Chat

Date Time Title Posts
09/8/202208:34TRADING4GOOD FROM LSE 2
13/4/202021:14Byotrol (BYOT) One to Watch on Wednesday 2
27/2/201619:04Byotrol:::::::::Cleaning Up45

Add a New Thread

Byotrol (BYOT) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type

Byotrol (BYOT) Top Chat Posts

Top Posts
Posted at 24/5/2023 19:22 by sikhthetech

It wasn't 24hrs.. It was SAME day. lol

They actually make the point about the approval being received AFTER CLOSE of business. Why highlight that it was received after 'close of business' on 22nd?????
Doesn't sound dodgy at

Director dealings 22nd May:

Receives approval on same day.

This approval was received by the Company after close of business, on 22 May 2023.

Posted at 17/5/2023 13:44 by football
Christ seeing what VP has done in the past year or so and the share price he makes DT look not so bad after allThe share price now is lower than before Brexit and Covid19(DT said it move the company forward 4/5yrs) when we had someone selling at any price to get out to settle a divorce and small institutions had to sell at any price due to Brexit What price any takeover now?
Posted at 21/4/2023 16:08 by 1gw
Great to see that Amati, one of byotrol's longest-standing shareholders and currently (as of the shareholder list published earlier this month) their 2nd-biggest with 25m shares, was a major contributor to last summer's convertible fund raise.

"In July, we completed a small follow-on investment, by way of a convertible loan note in Byotrol, the antimicrobial health product provider, to fund future growth and reach breakeven in the next 24 months. "

"The investment in Byotrol plc ("Byotrol") consists of 25,000,001 ordinary shares in Byotrol at fair value of £500,000 and 9% Convertible Loan Notes at fair value of £353,000. The convertible loan notes are convertible into ordinary shares at a conversion price of 3.25p."


So £500k from Directors/PDMRs, £350k from Amati, £150k from elsewhere.

Posted at 01/4/2023 10:35 by mudbath
Solvay might well acquire Byotrol somewhere down the line.

As things stand though I believe that BYOT is encountering varied headwinds.
It does not appear sustainable for such a small operation to carry 40 staff who will all be seeking a cost of living salary increase of up to double figures.At the same time other in house costs will be bounding upwards.

Quite how Byotrol will raise additional funds, should they be required, is too painful to even consider.

I therefore envisage a future comminication from the Company admitting to a parlous state of affairs along with their intsigating a strategic review, alongside a further helping hand by way of an element of additional finance from the Directors.

It is at this stage that BYOT might succumb to a cash offer, potentially in the region of 3p.
The alternatives would appear to be a pre pack or a delist.

With such a weak BoD it is difficult to see how this will play out.
As things stand though, I do not see the share price going anywhere soon apart from downwards.

Interesting, as always.

Posted at 18/3/2023 11:20 by mudbath
Byotrol has 40 employees as quoted in the 2022 Annual Report. (1gw)

Surely, for a £7million M/Cap company with revenues also of circa £7nillion that level of staffing is both outlandish and unsustainable, when compared to say Tristel.

The BYOT increasing cash usage reflects this human resource cost, with 2022 year end balance of £1.1 million subsequently increased by a further £1million (convertible loan receipt) being notably eroded to just £1.2 million at the interim stage.Given a similar decline, cash might be in the region of £300k at this months year end.

It could be that another raise is looming, possibly paired with a strategic review.
The current BYOT share price weakness is possibly reflecting these concerns.

No bargain then, until such time as Byotrol can demonstrate some (any) momentum.

Posted at 08/2/2023 18:12 by sikhthetech
"But the Company are of the opinion it’s their chemistry which is a positive"

The company may think that but, as I've stated many times, it's sales which matter.
Pointless having the best in the world if it doesn't sell.

A point which Tristel stated years ago, Sept 2020.:

sikhthetech - 06 Feb 2021 - 15:05:19 - 7555 of 8917
"Tristel can then use their international sale force to leverage up the Byotrol offering. Something Byotrol are just never going to be able to do alone."

Has there been a change to Tristel's stance on Byotrol partnership?

As Tristel commented in Sept, only a few months ago, the challenge here is whether the product is going to be a commercial success.

Tstl stated the position perfectly regarding tech and commercial success.

"The challenge we face with our partner Byotrol is essentially one of marketing communication: messaging. Today, UK hospitals use Jet because it is a high-performance, fast-acting biocide, effective against bacterial spores and compliant with every European legal requirement for disinfectants within one standard contact time of 1 minute, that is easy and convenient to use, and priced competitively to
pre-wetted wipes incorporating far less effective disinfectant chemistries."

"The intermediate level disinfectant formulation that has also been licensed from Byotrol will sit in one or more of the Cache Collection SKUs, alongside other formulation offers that come from our own stable of non-CLO2 chemistries. The Byotrol intermediate level formulation is very well-documented and supported by their technical team. "

"We are enthusiastic for the combinatorial proposition but it is important that we set expectations sensibly (we follow with interest the excitable dialogue on the share chat rooms): this is not a gamechanging technological advance for Tristel plc. The grounded truth is that with our partner Byotrol we have created something unique from a chemistry perspective"
" The commercial success of that proposition will take a long time to

Posted at 12/12/2022 08:48 by loafofbread
Quite an upbeat statement below. Onward and upward into next year.

Executive Chairman's report and financial review

The headline numbers for this report are ahead in many respects compared to the half year pre-Covid, but behind the half yearly results during the pandemic, including versus the first half of FYE March 2022.

The Company remains very well positioned strategically, with a solid balance sheet and net cash.

The 'boom' of Covid led to a period of over-supply in our industry once demand started to normalize. The excess stocks have now largely flowed-through but have generated consolidation as competitors and manufacturers who had over-extended themselves during the pandemic run out of cash. This consolidation is further driven by the increasingly demanding regulatory environment which many players do not have the resources or technical ability to succeed in.

Byotrol has long maintained a competitive technical and regulatory capability on a small cost base with high operational gearing and so is now well placed to benefit from these trends, to grow market share and to benefit from the consolidation. Our market share is now starting to grow and our financials are beginning to show the benefits of some fundamental operating changes made within the Company to maximise returns. These include:

-- Sharp increase in focus. We have reduced our technology platforms from seven to four, our operational segments from seven to three (animal health, specialist human health and consumer) and our SKUs by 25% so far.

-- Concomitant refocus of resources in sales and marketing, technical support and supply chain.

-- A resulting gross margin improvement of 3 percentage points despite the volatile supply chain and inflationary environment. Gross margin on product sales in H1 exceeded 40%, versus 37% in the prior year. Including provision releases year to date, reported gross margin for the period was 43.9%.

These improvements reflect what Byotrol has been positioning for over many years and that we are now seeing playing out in the market across Europe. Our lead market for products is now animal health, built on the brand equity from the acquired business and brands of Medimark Scientific, where we are substantially growing market share and are capitalizing on our first new surface sanitising technology platform launch under the 'Anigene' brand (see 'technology' section below).

Our strategy therefore remains in place and we will accelerate on the same path. Product sales are expected to increase steadily, especially in Professional, with the increased focus and better economies of scale leading to further improvement in margins. Those returns should also now be boosted through commission and license royalties from IP agreements finally bearing fruit. We now have an impressive portfolio of high-quality platform technologies, which we believe is yet to be fully recognized in the Company's valuation.

Your team therefore remains very confident in our positioning and in upcoming returns. This confidence was confirmed by management and team contributing over half of the funds for a GBP1m convertible bond financing completed in July this year, which solidifies our balance sheet, protects growth-oriented spending and protects us against further extraneous market shocks.

Results by segment


H1 revenues decreased to GBP1.90m from GBP2.61m, including GBP0.22m of royalty and licensing revenue compared to GBP0.75m in the comparable period. Gross profit on product sales (excluding license revenue) increased to GBP0.75m from GBP0.70m, reflecting the underlying improvement and simplification of the business.

Market conditions are largely back to normal in our traditional Professional market sectors, except in facilities management, where price competition is very strong and little recognition is being given to improved technology claims. We did expect this to be the case as the effects of the pandemic wore off and the UK economic outlook worsened and we have been consequently focussing sales and marketing efforts this year on animal health markets and on specialist niches in the higher margin human health markets. In the period under review Professional product revenue was split 52% animal health, 35% human health, 13% FM and other, versus 52%, 21% and 27% respectively in the previous half year.

The EU regulatory system is moving now in the direction that we have long been positioning for, and sales into customers with continental EU HQs have increased as a result. The UK's now-independent system is also becoming clearer.


H1 revenues decreased to GBP0.34m from GBP0.56m and gross profit to GBP0.14m from GBP0.20m, with gross margin increasing to 41% from 36%, a result (as in Professional) of focussing on higher margin product areas.

We have hired new leadership into our consumer division, tasked with selling our core technologies into retail and wholesalers under our brand and third-party brands. The opportunity here remains substantial, but given the high spend required to grow quickly, we are being very selective in the business that we pursue.

We therefore expect Consumer to remain niche for us in product sales in the short term, but with improving profitability, and we will exit channels where the spend and opportunity cost is not matched by the profit potential. This has led for instance to a gradual withdrawal from a well-known UK pet retailer, where we concluded that we would not be able to achieve a satisfactory return for the resources and risk required.

Technology Portfolio

The team has recognised for many years a need to focus technical effort and regulatory spend on a smaller number of platforms as the basis for our own product sales, especially as the regulatory deadlines approach. We are now taking the necessary decisions and have fixed on 3 core platforms that we will support through the final regulatory approvals in the EU:

-- HLD4 and its upgrade ("Cruise") for animal and human health - a high performance surface disinfectant, with broad spectrum anti-microbial activity and excellent value to customers on a per-use basis.

-- A new, natural and sustainable technology with excellent anti-microbial performance, especially against viruses, and we believe applicable in skin care and all surface care environments including humans, animals and specialist food environments. This is a new platform that we have been developing for 3 years and that is showing real promise in all targeted markets.

-- Invirtu hand sanitisers - alcohol free skin sanitization with an upgraded and more robust formulation, but with the same germ kill and dermatological benefits.

We continue to invest judiciously in other technical areas where we see potential from IP agreements and alliances, notably:

-- Seaweed antivirals - which is more appropriate for pharma, OTC and consumer applications than core Byotrol biocide markets, but that we still see as a valuable asset

-- Technologies that support long-lasting anti-microbial claims (notably Byotrol24 and Actizone)

-- Quaternary-free sanitisers for food markets
The IP commercialization effort for these technologies now has a dedicated sales team.

Intellectual Property Sales and Licensing

As reported in our year-end report in September (FYE March 2022), our licensing business has been held back by poor market conditions and by increasing customer focus on price and value in mass markets. This has meant some of our licensees are currently paying us minimum guaranteed royalties only. However, given the underlying regulatory position, we continue to see this as a core activity of Byotrol, offering 100% gross margin and broader distribution than we could achieve on our own.

The two most active IP-based projects are:

-- Solvay has now launched Actizone globally, the long-lasting antimicrobial surface sanitiser that Byotrol co-developed and that will pay Byotrol an ongoing commission on all Solvay sales. In October 2022 Solvay finally achieved US EPA and individual state approvals for Actizone, meaning that it is now the only globally available product of its type, applicable across consumer and professional markets worldwide. We await with interest new product launches (US and globally) and our first sizeable commission payments. We remain very limited by NDAs in what we can report on Solvay activity, as is Solvay with its own customers, but from publicly available sources we understand there are upcoming launches by household names in both consumer and business markets in the US, Europe and Asia.

-- IRI and the Company are facilitating a new EPA registration of the Byotrol 24 formulation in the US under a globally recognized business hygiene brand. We expect this to go into a test market in mid-2023, with a full launch in the US to follow should market testing prove successful.

Balance sheet

Our balance sheet was considerably strengthened in July by issuing GBP1m in convertible notes, to existing shareholders and to the Byotrol team. This was put in place as an insurance policy against further market shocks and to permit continued investment in sales, marketing and technology.

As with prior periods, we continue to invest in our IP and associated regulatory costs with GBP202k of additions into Intangible Assets in the first half of FY23 (see Note 7). Similarly, to support our growth strategy as outlined above, including our Anigene formulation re-launch, we have invested tactically in our inventory during the period resulting in a closing stock balance of GBP627k.

The above movements, combined with ongoing investment in strengthening the Byotrol team, resulted in a cash balance at period end of GBP1.2m.

Management Changes

On 22 November 2022 October we announced that John Langlands will be retiring from business life - and hence from the Byotrol board - on January 31, 2023 and that he would step-down with immediate effect from Non Executive Chairman of Byotrol plc. John has completed six years of service at the Company, one more year than he originally intended. He retires with the sincere thanks of the Directors.

We also announced the immediate promotion of our Chief Growth Officer (since January 2022) Vivan Pinto to CEO. Vivan brings many years of general management experience from multinationals such as J&J and Reckitt and has already been making a big impact upon the quality of the Company's operations.


The new management team has concentrated much of its efforts in this half year to improving the team, systems and processes - particularly in supply chain - and making the necessary decisions to rationalize the portfolio with focus on higher margin segments. We have made a lot of progress in this and are encouraged by the fact that gross margins are now on an upward trajectory.

Market demand is now solid in all areas except facilities management, which now accounts for only 13% of the Professional product portfolio. We will refocus in this area on niche segments with high margins and high barriers to entry as per our overall strategy. The favourable long-term demand trends in antimicrobial markets remain firmly in place.

We are now consistently winning product business in our main areas of focus in animal and human health. The re-launch of our animal healthcare formulation Anigene at the London Vet Show in November 2022 was very encouraging and is already leading to an upturn in orders.

We have had to learn to be patient on IP sales as we only make money when our licensees do. But the cash from minimum guarantees continues to boost our resources and the degree of investment by those licensees with regulators - especially in the US - remains very high.

Byotrol remains well-resourced to deliver further commercial progress; the long-term outlook for your company remains excellent.

David Traynor

Posted at 04/12/2022 14:37 by mudbath
Yes ghost, for it augurs well when our seller can dispose of his shares by the million and yet the BYOT share price remains stronger and in more demand than for quite some time.

Me too !!

Posted at 29/7/2022 16:00 by mudbath
Whilst I am happy to see the BYOT share price rising, the terms applicable to the Convertible Loan Note Fundraising smacks of selfish corporate greed by the BoD and other insiders.

If the future does indeed prove promising, then a discounted placing would have hurt no one beyond the short term; with the PI then not excluded from participating in in any forthcoming upturn.

If good news is about to be delivered then the BoD should be pilloried for taking advantage of their privileged knowledge.

Posted at 22/5/2022 21:01 by sikhthetech
"Then again I wasn't saying this was a buy at 6p 1gw, or selling TLY at 10p..... :)."

It wasn't 6p, 1gw was ramping Byot at 10p, stating Finncap are being conservative.. Also with his business model showing £17m annual revenues, which was conclusively proven to be complete BS...

All the while I warned of Jam tomorrow, other companies would adapt etc...
Byot share price fall was expected.

Lack of volume and no news so far, so nothing to back the recent share price rise..
Might be worth another punt...

Best to trade and not get caught again...

sikhthetech - 04 May 2021 - 21:44:20 - 8153 of 9727 BYOTROL-CAN DELIVER AMAZING

Well 1gw did say to correct him if it is inaccurate..
Maybe he likes jam, which is why he keeps posting about jam tomorrow...
Maybe time to ramp the online boots sales again...

1gw30 Sep '20 - 20:02 - 6961 of 8034
So on the product sales we seem to be running pretty well for the £12m revenue (which after all was just a run-rate calculation as I said), given 2H tends to be the bigger half anyway. finnCap are of course trying to be conservative about 2H, but if coronavirus cases continue to grow why wouldn't the sales continue at the £1m/month sort of level, especially if the supply chain is working better?
Happy to be corrected on any of this if you think it is inaccurate somehow. Did you even watch the presentation?

Byotrol share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |

V: D: 20230530 12:08:27